María José Forteza

Dr. María José Forteza

Division of Cardiovascular Medicine, Center for Molecular Medicine, Department of Medicine, Karolinska Institute, Karolinska University Hospital, 17164 Stockholm, Sweden
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in Cytokine
Verified
Journal Article
Closed access
RBRoland Baumgartner
Roland Baumgartner
MFMaría José Forteza
María José Forteza
DKDaniel Ketelhuth
Daniel Ketelhuth

1 July 2009 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
VBVicente Bodi
Vicente Bodi
JSJuan Sanchis
Juan Sanchis
JNJulio Núñez
Julio Núñez
LMLuis Mainar
Luis Mainar
MLMaria P. Lopez-Lereu
Maria P. Lopez-Lereu
ALAngel Llacer
Angel Llacer

16 April 2018 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
HLHarald Lund
Harald Lund
MPMelanie Pieber
Melanie Pieber
RPRoham Parsa
Roham Parsa
DGDavid Grommisch
David Grommisch
EEEwoud Ewing
Ewoud Ewing
RHRobert A. Harris
Robert A. Harris

1 May 2012 in JACC
Verified
Journal Article
Closed access
VBVicente Bodi
Vicente Bodi
JSJuan Sanchis
Juan Sanchis
JMJose M. Morales
Jose M. Morales
VMVannina G. Marrachelli
Vannina G. Marrachelli
JNJulio Núñez
Julio Núñez
DMDaniel Monleon
Daniel Monleon

14 August 2020 in Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
RBR. Baumgartner
R. Baumgartner
MBM. Berg
M. Berg
LML. Matic
L. Matic
KPK. P. Polyzos
K. P. Polyzos
MFMaría José Forteza
María José Forteza
DKDaniel Ketelhuth
Daniel Ketelhuth
Background: The metabolism of tryptophan (Trp) along the kynurenine pathway has been shown to carry strong immunoregulatory properties. Several experimental studies indicate that this pathway is a major regulator of vascular inflammation and influences atherogenesis. Knowledge of the role of this pathway in human atherosclerosis remains incomplete.Objectives: In this study, we performed a multiplatform analysis of tissue samples, in vitro and in vivo functional assays to elucidate the potential role of the kynurenine pathway in human atherosclerosis.Methods and results: Comparison of transcriptomic data from carotid plaques and control arteries revealed an upregulation of enzymes within the quinolinic branch of the kynurenine pathway in the disease state, whilst the branch leading to the formation of kynurenic acid (KynA) was downregulated. Further analyses indicated that local inflammatory responses are closely tied to the deviation of the kynurenine pathway in the vascular wall. Analysis of cerebrovascular symptomatic and asymptomatic carotid stenosis data showed that the downregulation of KynA branch enzymes and reduced KynA production were associated with an increased probability of patients to undergo surgery due to an unstable disease. In vitro, we showed that KynA‐mediated signalling through aryl hydrocarbon receptor (AhR) is a major regulator of human macrophage activation. Using a mouse model of peritoneal inflammation, we showed that KynA inhibits leukocyte recruitment.Conclusions: We have found that a deviation in the kynurenine pathway is associated with an increased probability of developing symptomatic unstable atherosclerotic disease. Our study suggests that KynA‐mediated signalling through AhR is an important mechanism involved in the regulation of vascular inflammation.

1 October 2019 in Cardiovascular Research
Verified
Journal Article
Open access
MBMartin Berg
Martin Berg
KPKonstantinos Polyzos
Konstantinos Polyzos
HAHanna Agardh
Hanna Agardh
RBRoland Baumgartner
Roland Baumgartner
MFMaría José Forteza
María José Forteza
DKDaniel Ketelhuth
Daniel Ketelhuth
Aims: Atherosclerosis is a chronic inflammatory disease involving immunological and metabolic processes. Metabolism of tryptophan (Trp) via the kynurenine pathway has shown immunomodulatory properties and the ability to modulate atherosclerosis. We identified 3-hydroxyanthranilic acid (3-HAA) as a key metabolite of Trp modulating vascular inflammation and lipid metabolism. The molecular mechanisms driven by 3-HAA in atherosclerosis have not been completely elucidated. In this study, we investigated whether two major signalling pathways, activation of SREBPs and inflammasome, are associated with the 3-HAA-dependent regulation of lipoprotein synthesis and inflammation in the atherogenesis process. Moreover, we examined whether inhibition of endogenous 3-HAA degradation affects hyperlipidaemia and plaque formation.Methods and results: In vitro, we showed that 3-HAA reduces SREBP-2 expression and nuclear translocation and apolipoprotein B secretion in HepG2 cell cultures, and inhibits inflammasome activation and IL-1β production by macrophages. Using Ldlr−/− mice, we showed that inhibition of 3-HAA 3,4-dioxygenase (HAAO), which increases the endogenous levels of 3-HAA, decreases plasma lipids and atherosclerosis. Notably, HAAO inhibition led to decreased hepatic SREBP-2 mRNA levels and lipid accumulation, and improved liver pathology scores.Conclusions: We show that the activity of SREBP-2 and the inflammasome can be regulated by 3-HAA metabolism. Moreover, our study highlights that targeting HAAO is a promising strategy to prevent and treat hypercholesterolaemia and atherosclerosis.